EP2125135A1 - Appareil de filtration d'un fluide biologique à grande capacité - Google Patents

Appareil de filtration d'un fluide biologique à grande capacité

Info

Publication number
EP2125135A1
EP2125135A1 EP07751426A EP07751426A EP2125135A1 EP 2125135 A1 EP2125135 A1 EP 2125135A1 EP 07751426 A EP07751426 A EP 07751426A EP 07751426 A EP07751426 A EP 07751426A EP 2125135 A1 EP2125135 A1 EP 2125135A1
Authority
EP
European Patent Office
Prior art keywords
biological fluid
outlet
inlet
fluid filtration
flow path
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07751426A
Other languages
German (de)
English (en)
Other versions
EP2125135A4 (fr
Inventor
Peter Zuk Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hemerus Medical LLC
Original Assignee
Hemerus Medical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemerus Medical LLC filed Critical Hemerus Medical LLC
Publication of EP2125135A1 publication Critical patent/EP2125135A1/fr
Publication of EP2125135A4 publication Critical patent/EP2125135A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A61M1/3627—Degassing devices; Buffer reservoirs; Drip chambers; Blood filters
    • A61M1/3633—Blood component filters, e.g. leukocyte filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/0209—Multiple bag systems for separating or storing blood components
    • A61M1/0218—Multiple bag systems for separating or storing blood components with filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A61M1/3627—Degassing devices; Buffer reservoirs; Drip chambers; Blood filters
    • A61M1/3633—Blood component filters, e.g. leukocyte filters
    • A61M1/3635—Constructional details
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/0209—Multiple bag systems for separating or storing blood components
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2323/00—Details relating to membrane preparation
    • B01D2323/42—Details of membrane preparation apparatus

Definitions

  • This invention relates to the filtration field, and more particularly, to an improved low hold up biological fluid filtration system, including a low hold up double sided biological fluid filter device lacking a partition wall capable of filtering biological fluids, including the removal of components or chemicals from blood or blood products, including the removal of leukocytes from packed red cells, and prions from blood or blood products.
  • Double sided biological fluid filtration devices that include a single inlet and a single outlet with a partition wall are disclosed in patent serial no. US 6,660,171 B2, entitled HIGH CAPACITY GRAVITY FEED FILTER FOR FILTERING BLOOD AND BLOOD PRODUCTS, filed on March 27, 2001.
  • Double sided biological fluid filtration devices that contain a partition wall are also disclosed in patent application no. 10/934,881, entitled A BIOLOGICAL FLUID FILTRATION APPARATUS, filed on September 03, 2004.
  • Double sided biological fluid filtration devices that contain a partition wall are also disclosed in PCT application no. PCT/US2004/029026, entitled A BIOLOGICAL FLUID FILTRATION APPARATUS, filed on September 07, 2004.
  • Application no. 10/934,881 and application no. PCT/US2004/029026 disclose a double sided biological fluid filtration device that includes two independent fluid flow paths separated by a partition wall with each fluid flow path containing a separate inlet and outlet, thereby allowing two units of biological fluid including blood or blood product to be independently filtered.
  • Patent no. US 6,231 ,770 B1 describes a double sided biological fluid filtration device that lacks a partition wall that includes a single inlet and a single outlet with two fluid flow paths between the inlet and outlet.
  • the disadvantage of this type of device is that if two units of blood or blood product are filtered through this device and collected into two separate receiving blood bags, the first unit will be filtered by the device with the filter elements of the device in a relatively non- fouled condition, and the second unit will be filtered by the device with the filter elements in a relatively fouled condition. Therefore the flow rate through the device for the first unit will be faster than the flow rate for the second unit. Hence the filtration efficiency may be different between the first and second units. Therefore, when the device is used for leukocyte reduction the leukocyte reduction rate may be different for the first and second units.
  • a biological fluid filtration system including a biological fluid filtration device that lacks a partition wall, and that includes a single inlet and a double outlet, that will filter two units of biological fluid including blood or blood product, with both units being filtered simultaneously at approximately the same flow rate, and that will run automatically, and minimize hold up volume. It is also an object of the present invention to provide a single vent filtration device that can vent the two fluid flow paths of a biological fluid filtration device that includes two independent fluid flow paths. It is a further object of the present invention to provide a means to limit the flow rate through the device by including flow restriction downstream of the biological fluid filtration media in the device.
  • a Double Sided Biological Fluid Filtration Device (hereinafter referred to as BFFD) as used herein means a filtration device comprising a housing containing an inlet and two outlets, with a first fluid flow path defined between the inlet and the first outlet, with a second fluid flow path defined between the inlet and the second outlet, with a first biological fluid filtration media interposed between the inlet and the first outlet and across the first fluid flow path, with the first biological fluid filtration media sealed to the housing to prevent the flow of biological fluid between the housing and the first biological fluid filtration media, with a second biological fluid filtration media interposed between the inlet and the second outlet and across the second fluid flow path, with the second biological fluid filtration media sealed to the housing to prevent the flow of biological fluid between the housing and the second biological fluid filtration media.
  • BFFD Double Sided Biological Fluid Filtration Device
  • the biological fluid filtration device being capable of filtering biological fluids, including blood or blood products to remove leukocytes, prions, other blood components, cells, and chemical agents which may be used to treat the biological fluid, from the biological fluid.
  • biological fluids including blood or blood products to remove leukocytes, prions, other blood components, cells, and chemical agents which may be used to treat the biological fluid, from the biological fluid.
  • BFFD may also be used as shorthand for other types of Biological Fluid Filtration Devices.
  • Biological Fluid Filtration Media means a porous filtration media capable of filtering biological fluids, including blood or blood products to remove leukocytes, prions, other blood components, cells, and chemical agents which may be used to treat the biological fluid, from the biological fluid.
  • the biological fluid filtration media comprises at least one filter element, with each filter element containing one or more layers of porous filter material of the same type.
  • the biological fluid filtration media may contain more than one filter element, with each filter element containing a different type of filter material. Any of the various types of biological fluid filtration media that contain one or more filter elements of the same or different types as disclosed in patent application no. 10/934,881 or in application no.
  • Vent Filtration Media as used herein means the filtration media used in a vent filter device.
  • the media may be microporous filter material made from a material such as Teflon or PVDF, preferably with a pore size of 0.2 ⁇ or smaller, or the media may be a depth media, such as cotton, spun bound polyester, or a molded depth media such as Porex.
  • Housing as used herein means the enclosure into which the filtration media is sealed.
  • the housing of a BFFD may contain an inlet and two outlets, with a first fluid flow path defined between the inlet and the first outlet, with a first BFFM interposed between the inlet and the first outlet and across the first fluid flow path, and sealed to the housing to prevent the flow of biological fluid between the housing and the first BFFM; with a second fluid flow path defined between the inlet and the second outlet, with a second BFFM interposed between the inlet and the second outlet and across the second fluid flow path, and sealed to the housing to prevent the flow of biological fluid between the housing and the second BFFM.
  • the housing does not contain a partition wall.
  • the housing may be made from a rigid material such as stainless steel or aluminum, or from any rigid molded plastic material such as Acrylic, Polycarbonate, Polypropylene, Polyethylene.
  • the housing of a vent filtration device contains a vent port in fluid flow communication with atmosphere, and a system port in fluid flow communication with the biological fluid filtration system, with a fluid flow path defined between the vent port and the system port, with a vent filtration media interposed between the vent port and the system port and across the fluid flow path, and sealed to the housing to prevent the flow of biological fluid or gas between the vent filtration media and the housing.
  • Biological Fluid as used herein means any type of biological liquid, including blood or blood product, and including leukocyte containing suspensions or a prion containing suspensions.
  • Leukocyte Containing Suspension as used herein means a liquid in which leukocytes are suspended.
  • leukocyte-containing suspensions include whole blood; red cell products, such as concentrated red cells, washed red cells, leukocyte-removed cells, thawed red cell concentrate and thawed red cell suspension; plasma products, such as platelet-poor plasma, platelet-enriched plasma, fresh lyophilized plasma, fresh liquid plasma and cryoprecipitate; and other leukocyte-containing blood products, such as concentrated platelet cells, buffy coat and buffy coat-removed blood.
  • the leukocyte-containing suspension to be filtered by the devices and systems described in the present invention is not limited to the above examples.
  • DDD Diaphragm Draining Device
  • the foregoing problems of the prior art are solved, and the objects of the present invention are achieved, by use of a biological fluid filtration device (BFFD) and system constructed in accordance with the principles of the present invention.
  • the biological fluid filtration system of the present invention is capable of filtering biological fluids, including blood or blood products to remove leukocytes, prions, other blood components, cells, and chemical agents which may be used to treat the biological fluid, from the biological fluid.
  • the biological fluid filtration system includes a feed container, normally a collapsible blood bag and one or more receiving containers, normally a collapsible blood bag or bags with a BFFD interposed between the feed and receiving blood bags.
  • the BFFD includes a housing lacking a partition wall having an inlet and two outlets, with a first fluid flow path defined between the inlet and the first outlet, with a first biological fluid filtration media (BFFM) is interposed between the inlet and the first outlet, and across the first fluid flow path; and with a second fluid flow path defined between the inlet and the second outlet, with a second biological fluid filtration media (BFFM) interposed between the inlet and the second outlet, and across the second fluid flow path.
  • BFFM biological fluid filtration media
  • the BFFM's may contain one filter element or multiple filter elements of different types.
  • the housing also includes a chamber located between the inlet and the upstream surface of the two BFFM's.
  • a first flow restriction may be located downstream of the first BFFM, and a second flow restriction may be located downstream of the second BFFM.
  • the biological fluid filtration system may also include a means to automatically drain the upstream chamber of the BFFD when the filtration cycle is complete.
  • the draining means may include a diaphragm draining device (D D D) that includes a built in flow restriction. Any of the various types of in line automatic draining means that are disclosed in patent application no. 10/934 ⁇ 881 or in application no. PCT/US2004/029026 may be used as automatic draining means in this application.
  • the BFFM may include a first filter element composed of one or more layers of porous filter material of a first pore size, followed by a second filter element composed of one or more layers of porous filter material of a second pore size smaller than that of the first pore size, followed by a third filter element composed of one or more layers of porous filter material of a third pore size larger than that of the second pore size, followed by a fourth filter element composed of one or more layers of porous filter material of a fourth pore size smaller than the pore size of the second filter element.
  • the first filter element may include means to remove gels from blood or blood product
  • the second filter element may include means to remove microaggregates from blood or blood products
  • the fourth filter element may include means to remove leukocytes from blood or blood products
  • the third filter element acts as a flow distribution layer.
  • the BFFM is not restricted to the type just described, any suitable type of BFFM for a particular application may be used.
  • FIG. 1 is a side view of a first embodiment of a biological fluid filtration system constructed in accordance with the principles of the present invention, usable for the filtration of biological fluids, containing a feed blood bag, a first receiving blood bag, a second receiving blood bag, with the first embodiment of a BFFD interposed between the feed blood bag and the receiving blood bags, and with a diaphragm draining device (DDD) that includes a built in flow restriction interposed between the feed blood bag and the BFFD;
  • DDD diaphragm draining device
  • Figure 2 is a cross-sectional view of the first embodiment of a BFFD constructed in accordance with the principles of the present invention, usable for the filtration of biological fluids;
  • Figure 3 is an isometric view with portions thereof removed of the DDD shown in Figure 1 ;
  • Figure 4 is a isometric view with portions thereof removed of the housing inlet half of the BFFD shown in Figure 2;
  • Figure 5 is an isometric view with portions thereof removed of the first housing outlet half of the BFFD shown in Figure 2, the second housing outlet half is identical to the first housing outlet half;
  • Figure 6 is a isometric view with portions thereof removed of a housing inlet half including a baffle, that can be used to replace the housing inlet half shown in Figure 4;
  • FIG. 7 is a side view of a second embodiment of a biological fluid filtration system constructed in accordance with the principles of the present invention, usable for the filtration of biological fluids, containing a feed blood bag, a first receiving blood bag, a second receiving blood bag, with a second embodiment of a BFFD interposed between the feed blood bag and the receiving blood bags, with a diaphragm draining device (DDD) that includes a built in flow restriction interposed between the feed blood bag and the BFFD;
  • DDD diaphragm draining device
  • Figure 8 is a cross-sectional view of a single sided BFFD constructed in accordance with the principles of the present invention, that includes a flow restriction in the outlet, usable for the filtration of biological fluids.
  • FIG. 1 One embodiment of the biological fluid filtration system constructed in accordance with the principles of the present invention, is shown in Figure 1 through Figure 5.
  • Biological fluid filtration system 1000 shown in Figure 1 contains feed blood 98, first receiving blood bag 99 and second receiving blood bag 99a. Interposed between feed blood bag 98 and the two receiving blood bags is a biological fluid filtration device (BFFD) 100.
  • Diaphragm draining device (DDD 50) may be interposed between feed blood bag 98 and BFFD 100.
  • First length of tubing 81 connects the outlet of feed blood bag 98 to the inlet tube socket 51 of DDD 50.
  • Second length of tubing 81a connects outlet tube socket tube socket 52 of DDD 50 to the inlet tube socket 6 of BFFD 100.
  • a third length of tubing 82 connects first outlet tube socket 28 of BFFD 100 to the inlet of first receiving blood bag 99.
  • a fourth length of tubing 82a connects second outlet tube socket 28a of BFFD 100 to the inlet of second receiving blood bag 99a.
  • the outlet end of tubing 82 could be connected to the first port of a tubing Tee or tubing Y, with the outlet end of tubing 82a connected to the second port of the tubing Tee or tubing Y 1 with the third port of the tubing Tee or Y connected the inlet of a common receiving blood bag.
  • Tubing 81 may contain tube clamp 95
  • tubing 82 may contain tube clamp 96
  • tubing 82a may contain tube clamp 96a.
  • Diaphragm draining device 50 could be replaced with a vent filtration device, or could be eliminated entirely.
  • BFFD 100 contains a rigid housing that includes housing inlet half 1, first housing outlet half 20, and second housing outlet half 20a.
  • Housing seal surface 19 of housing inlet half 1 is bonded to housing seal surface 29 of first housing outlet half 20.
  • Housing seal surface 19a of housing inlet half 1 is bonded to housing seal surface 29a of second housing outlet half 20a.
  • the bonds are preferably ultrasonic welds but could be a heat bonds, glue bonds, solvent bonds, or any other type of leak tight bond.
  • housing inlet half 1 contains first filter well 11 bounded by inner side wall 8 and by a plane that goes through filter seal surface 7. Housing inlet half 1 also contains second filter well 11a bounded by inner side wall 8a and by a plane that goes through filter seal surface 7a.
  • Upstream chamber 13 is bounded by inner surface 10a of inner wall 10 of housing inlet half 1, and by upstream surface 16b of filter element 16, and by upstream surface 16ab of filter element 16a.
  • upstream chamber contains a space between the upstream surface of the first BFFM and the upstream surface of the second BFFM, with the upstream surface of the first BFFM opposing the upstream surface of the second BFFM.
  • Inlet 5 is in fluid flow communication with upstream chamber 13.
  • the outlet end of tubing 81a is inserted into and bonded to inlet tube socket 6.
  • Inlet 5 is shown located at the top of upstream chamber 13 and on the vertical center line of housing inlet half 1 , it could however, be located anywhere between the top and the bottom of upstream chamber 13, and could also be located to the right or to the left of the vertical center line.
  • BFFD 100 contains first housing outlet half 20 and second housing outlet half 20a.
  • Housing outlet half 20a is identical to housing outlet half 20.
  • Housing outlet half 20 contains circular outlet channel 25 and outlet 27.
  • Outlet 27 may contain a flow restriction as shown in Figure 2 and Figure 5.
  • Circular outlet channel 25 is in direct fluid flow communication with outlet 27, and the portion of circular outlet channel 25 that adjoins outlet 27 has a cross-sectional flow area that is greater than the cross-sectional flow area of outlet 27.
  • Housing outlet half 20 also contains a plurality of open top closed bottom vertical channels 22 and 22a. One end of each of the vertical channels 22 and 22a is in fluid flow communication with circular outlet channel 25.
  • the upper part of circular outlet channel 25 increases in width to accommodate the flow of biological fluid from vertical channels 22 and 22a.
  • the width of the remainder of circular outlet channel 25 (i.e. the lower part of circular outlet channel 25) is preferably equal to the width of the vertical channels.
  • the two outermost vertical channels designated as vertical channels 22a adjoin circular outlet channel 25 where the width of circular outlet channel 25 is equal to the width of the vertical channels.
  • the outlet channel and the vertical channels combined, create a filter under drain structure that is cut into wall 37 of housing outlet half 20 so that the inner surface of all of the channels lies below inner wall 21 of housing outlet half 20 as shown in Figure 5.
  • the cross sectional area the outlet channel and of the vertical channels is defined by the inner surface of each channel and by the downstream surface of the BFFM in contact with said wall.
  • housing outlet half 20 also contains filter seal surface 24. Because housing outlet half 20 does not contain an open chamber or pienum downstream of the BFFM, hold up volume of biological fluid will be minimized. Housing outlet half 20 of this application is identical to housing outlet half 220 that is disclosed in patent application no. 10/934,881 and in application no. PCT/US2004/029026, with the exception that housing outlet half 20 includes a flow restriction in the outlet.
  • a first biological fluid filtration media (BFFM) that contains at least one filter element is interposed between inlet 5 and first outlet 27, and is sealed to the housing to prevent the flow of unfiltered biological fluid from flowing between the housing and the first BFFM to prevent bypass of unfiltered biological fluid around the first BFFM.
  • a second biological fluid filtration media (BFFM) that contains at least one filter element is interposed between inlet 5 and second outlet 27a, and is sealed to the housing to prevent the flow of unfiltered biological fluid from flowing between the housing and the second BFFM to prevent bypass of unfiltered biological fluid around the second BFFM.
  • the first BFFM shown in Figure 2 contains filter elements 16 and 18.
  • the filter elements may all be of the same type or may be different types filter elements.
  • filter element 16 may be a microaggregate filter element and filter elements 18 may be leukocyte removing filter elements.
  • Each filter element contains an upstream surface designated as upstream surface 16b for filter element 16, a downstream surface designated as downstream surface 16c for filter element 16, and a perimeter surface designated as perimeter surface 16d for filter element 16.
  • the downstream surface of the BFFM shown as downstream surface 18c of filter element 18 is in contact with inner wall 21 of housing outlet half 20. Because the downstream surface of the BFFM contacts inner wall 21 of housing outlet half 20, BFFD 100 does not contain an open chamber or plenum downstream of the BFFM. The air or liquid that is forced through the BFFM must pass through the vertical channels and the circular outlet channel before flowing into outlet 27 of BFFD 100.
  • the at least one filter element may be sealed to the housing with an interference fit between the perimeter surface of the at least one filter element and inner side wall 8 of housing inlet half 1 as shown for filter elements 18, or the at least one filter element may be sealed to the housing with a compression seal by compressing the outer periphery of the at least one filter element with filter seal surface 7 of housing inlet half 1 as shown for filter element 16, or the at least one filter element may be sealed to the housing using a heat seal, an ultrasonic weld, a glue seal, a solvent seal, a radio frequency weld, or any other type of leak tight seal.
  • a combination of sealing methods may also be used to seal the at least one filter element to the housing.
  • the second BFFM is preferably the same as the first BFFM and is preferably sealed to the housing the same way that the first BFFM is sealed to the housing.
  • a gel filter element followed by a microaggregate filter element, followed by a flow distribution filter element, followed by a leukocyte removing filter element could be used in the present invention.
  • a first fluid flow path is defined between inlet 5 of BFFD 100 and first outlet 27 of BFFD 100 with the at least one filter element of the first BFFM interposed between inlet 5 and first outlet 27, and across the fluid flow path.
  • the first fluid flow path flows from inlet 5, into upstream chamber 13, through the at least one filter element of the first BFFM, into vertical channels 22 and 22a, into circular outlet channel 25, and then into outlet 27 which may contain a flow restriction, all of first housing outlet half 20.
  • a second fluid flow path is defined between inlet 5 of BFFD 100 and second outlet 27a of BFFD 100 with the at least one filter element of the second BFFM interposed between inlet 5 and second outlet 27a, and across the second flow path.
  • the second fluid flow path flows from inlet 5, into upstream chamber 13, through the at least one filter element of the second BFFM, into vertical channels 22 and 22a, into circular outlet channel 25, and then into outlet 27a which may contain a flow restriction, all of second housing outlet half 20a.
  • FIGS 1 and Figure 3 show diaphragm draining device 50 (hereinafter referred to as DDD 50).
  • DDD 50 contains rigid housing inlet half 58, rigid housing outlet half 59 and flexible diaphragm 53.
  • Housing outlet half 59 contains inlet tube socket 51, outlet tube socket 52, first channel 54, second channel 55, third channel 56, and common node 60.
  • Common node 60 places each one of the three channels in fluid flow communication with the other two channels.
  • Second channel 55 contains a flow restriction shown as a channel that is longer and smaller in diameter than the first and third channels.
  • the first channel may be referred to as inlet 54
  • the second channel may be referred to as outlet 55
  • the third channel may be referred to as side port 56.
  • Housing outlet half 59 combines three tube connector 1650 and housing outlet half 1820 that are disclosed in patent application no. 10/934,881 and in application no. PCT/US2004/029026 into a single component.
  • the shape of the three tube connector made up of first channel 54, second channel 55, and third channel 56, is shown as a tee, but is not restricted to this shape, it could be in the form of a Y, for example.
  • Figure 3 shows DDD 50 in its normal state with housing inlet half 58 sealed to housing outlet half 59.
  • the seal is preferably an ultrasonic seal, but could be a heat seal, a solvent seal, a glue seal, or a compression seal between housing inlet half 58 and housing outlet half 59, or any other type of leak tight seal.
  • Flexible diaphragm 53 may be molded from a flexible rubber material such as silicone rubber, or it may be molded or thermo formed from a material such as PVC, polyethylene, or polypropylene, but is not limited to these materials. Flexible diaphragm 53 is preferably shaped so that in its normal state outer surface 66 conforms to inner surface 67 of housing inlet half 58. Flexible diaphragm 53 contains flange 68 which may be bonded to housing inlet half 58 or to housing outlet half 59. The bond may be a heat bond, an ultrasonic bond, a glue bond, a. solvent bond, or any other type of leak tight bond. Alternately, flange 68 may be compression sealed between housing inlet half 58 and housing outlet half 59.
  • flange 68 may be compression sealed between housing inlet half 58 and housing outlet half 59.
  • FIG. 3 shows DDD 50 in its normal state with outer surface 66 of diaphragm 53 in contact with inner surface 67 of housing inlet half 58.
  • DDD 50 contains chamber 63 that is in fluid flow communication with third channel 56.
  • chamber 63 is filled with a gas (normally sterile air) at atmospheric pressure.
  • a third fluid flow path is defined between feed blood bag 98 and common node 60 of housing outlet half 59 of DDD 50, with the flow in the third fluid flow path flowing from feed blood bag 98 through tubing 81 , into inlet 54 of DDD 50, to common node 60.
  • a fourth fluid flow path is defined between common node 60 of DDD 50 and inlet 5 of BFFD 100, with the flow in the fourth fluid flow path flowing from common node 60, through outlet 55 of DDD 50 (including the flow restriction), through tubing 81a, to inlet 5 of BFFD 100.
  • a fifth fluid flow path is defined between the common node and chamber 63 of DDD 50, with the flow of the fifth fluid flow path flowing from chamber 63, through third channel 56, to the common node 60.
  • biological fluid filtration system 1000 functions as follows.
  • the user will purchase the system with all components as shown in Figure 1 , less feed blood bag 98.
  • the user will connect tubing 81 to outlet 92 of feed blood bag 98 in a manner known in the art.
  • Feed blood bag 98 may be hung from a hook on a blood bag pole, and first receiving blood bag 99 and second receiving blood bag 99a may be placed on a table top or the like, so that the various components of the system will be positioned as shown in Figure 1.
  • feed blood bag 98 may be part of a set that includes all of the components shown in Figure 1, in which case the blood or blood product that is collected from a donor will be collected in feed blood bag 98.
  • Tube clamp 95 should be closed before connecting tubing 81 to feed blood bag 98. Before opening tube clamp 95 to start the flow of biological fluid (i.e. liquid) through the system, tube clamps 96 and 96a should be open. [0034] When tube clamp 95 is opened biological fluid (i.e. liquid) will flow from feed blood bag 98, through tubing 81, into inlet 54 of DDD 50, through outlet 55 of DDD 50, through tubing 81a, into inlet 5 of BFFD 100, into upstream chamber 13 of BFFD 100. Because outlet 55 of DDD 50 contains a flow restriction, the flow downstream of the inlet and downstream of the side port of the DDD will be automatically restricted, and a positive pressure will be created at common node 60 of DDD 50.
  • biological fluid i.e. liquid
  • the first condition is: If the volume of upstream chamber 13 is small enough, and if the initial combined flow rate of the first and second BFFM's does not exceed the flow rate of the biological fluid entering inlet 5, upstream chamber 13 of BFFD 100 will rapidly fill with biological fluid from the bottom up. As upstream chamber 13 fills from the bottom up, the initial air in upstream chamber 13 will be displaced by the biological fluid filling upstream chamber 13. A portion of the displaced air will be forced through the first BFFM, into vertical channels 22 and 22a, into circular outlet channel 25, and then into first outlet 27, all of first housing outlet half 20.
  • the biological fluid in upstream chamber 13 will be pressurized, with the pressure at the bottom of upstream chamber 13 being proportional to the distance from the top of the biological fluid in feed blood bag 98 to the bottom of upstream chamber 13, and with the pressure at the top of upstream chamber 13 being proportional to the distance from the top of the biological fluid in feed blood bag 98 to the top of upstream chamber 13. Hence the pressure at the top of upstream chamber 13 will be less than the pressure at the bottom of upstream chamber 13.
  • the positive pressure in upstream chamber 13 will cause the biological fluid to flow through the first and second BFFM's over the entire surface area of the first and second BFFM's and to displace the air within the pores of the first and second BFFM's with biological fluid, thereby wetting the first and second BFFM's from the upstream side of the first and second BFFM's to the downstream side of the first and second BFFM's.
  • the BFFM's will first become completely wetted from the upstream surface of the BFFM's to downstream surface of the BFFM's at the bottom of the BFFM's. If the width of vertical channels 22 and 22a of the respective housing outlet halfs is sufficiently small, and the depth of vertical channels 22 and 22a is sufficiently shallow, so that the cross-sectional flow area of vertical channels 22 and 22a is sufficiently small, and if the distance between vertical channels 22 is sufficiently large, the path of least resistance for continued biological fluid flow through the BFFM's will be through the capillaries of the BFFM's in both the horizontal and vertical directions and not through the vertical channels; because if the cross-sectional flow area of the vertical channels is sufficiently small, the displaced air flowing into and through the vertical channels will create a sufficiently high positive pressure in the vertical channels to prevent biological fluid from entering the vertical channels.
  • the downstream surface of the BFFM's will therefore wet from the bottom up and the displaced air that was within the BFFM's will continue to flow into the vertical channels, and into the circular outlet channel, and then into the outlets.
  • air flow ' through the two outermost vertical channels 22a will stop because the downstream surface of the BFFM's below the top of the two outermost vertical channels will be wetted. Therefore the pressure in the two outermost vertical channels will decrease allowing biological fluid to enter the two outermost vertical channels from the bottom up, thereby displacing the air that was in the two outermost vertical channels.
  • the first and second BFFM's will continue to wet vertically.
  • the initial flow through circular outlet channel's 25, and through outlet 27 and 27a will first be air, and then be a mixture of air and biological fluid, and finally biological fluid only, so that the initial flow into tubing 82 and 82a will first be air and then consist of alternate segments of biological fluid and air, and finally consist of biological fluid only.
  • the flow of biological fluid through them will be uniform over their entire surface area so that the entire surface area of the BFFM's will be used to filter the biological fluid, thereby utilizing the BFFM's most efficiently.
  • the present invention is not limited to the filter underdrain shown in Figure 5.
  • any of the filter underdrains disclosed in patent application no. 10/934,881, or in application no. PCT/US2004/029026, or in patent no. 6,660,171 could also be used in the present invention.
  • any other type of filter underdrain that provides sufficient support for the BFFM, and provides a fluid flow means between the downstream of the BFFM and the respective outlet could also be used.
  • BFFD 100 will wet as described in the first condition above, with the initial flow rates (i.e. the flow rates before the BFFM's have been wetted) being as described in the first condition.
  • the flow rate through the BFFM's may increase so that the combined flow rate through the first and second BFFM will exceed the flow rate of biological fluid entering chamber 13 through inlet 5.
  • biological fluid will initially fill chamber 13 from the bottom to the top, and then after the BFFM's have been wetted, the liquid level in chamber 13 will drop to a level below the top of chamber 13.
  • the flow rate of biological fluid through the portion of the BFFM's below the top of the liquid level in chamber 13 will be much greater than the flow rate of biological fluid through the portion of the BFFM's above the top of the liquid level in chamber 13, so that the portions of the BFFM's above the liquid level will not be properly utilized.
  • BFFD 100 is used to remove leukocytes from blood or blood product
  • the leukocyte removing capability of the BFFM's may be reduced in the second condition when measured against the first condition above.
  • the filtered blood or blood product in the receiving blood bag's may contain more leukocytes than the filtered blood or blood product in the receiving blood bag's under the first condition.
  • the second condition can be rectified by adding flow restrictions to first outlet 27 and second outlet 27a as shown in Figure 2.
  • the flow restrictions are shown in Figure 2 as long small diameter outlets.
  • the flow restrictions should be sized so that the combined flow rate of biological fluid through the first and second BFFM's, and therefore through outlets 27 and 27a, is less than or equal to the flow rate of biological fluid entering chamber 13 through inlet 5.
  • the flow restrictions could be located anywhere downstream of the BFFM's. For example a first flow restriction could be located in tubing 82 between outlet 27 and first receiving blood bag 99, and a second flow restriction could be located in tubing 82a between outlet 27a and second receiving blood bag 99a.
  • tubing 82 and tubing 82a could have a smaller inside diameter than tubing 81 and tubing 81a to create the restrictions downstream of the first and second BFFM's respectively.
  • Flow restrictions could also be used downstream of the BFFM in a single sided BFFD for the same reasons just described.
  • a flow restriction could be added downstream of the BFFM in any of the single sided devices disclosed in patent application no. 10/934,881 or in application no. PCT/US2004/029026.
  • the third condition that can occur after tube clamp 95 is opens is: If the volume of upstream chamber 13 is large enough, the BFFM's will be wetted before the liquid level in upstream chamber reaches the top of upstream chamber 13, by a combination of liquid flow through the BFFM's below the liquid level in upstream chamber 13, and capillary wetting above the liquid level, thereby allowing the air to be purged from the BFFM's. Once the BFFM's have been wetted, the air in upstream chamber 13 above the liquid level will be trapped in upstream chamber 13, because the wetted BFFM's will not allow this air to be purged from upstream chamber 13.
  • the flow rate of biological fluid through the portion of the BFFM's below the top of the liquid level in chamber 13 will be much greater than the flow rate of biological fluid through the portion of the BFFM's above the top of the liquid level in chamber 13, so that the portions of the BFFM's above the liquid level will not be properly utilized.
  • BFFD 100 is used to remove leukocytes from blood or blood product
  • the leukocyte removing capability of the BFFM's may be reduced in the third condition when measured against the first condition above.
  • the filtered blood or blood product in the receiving blood bag's may contain more leukocytes than the filtered blood or blood product in the receiving btood bag's under the first condition.
  • the third condition can be rectified by reducing the volume of upstream chamber 13.
  • the width of inner surface 10a of housing inlet half 1 i.e. the distance between filter seal surface 7 and fitter seal surface 7a
  • the volume of upstream chamber 13 may be minimized by adding baffle 12 to inner wall 10 of housing inlet half 1a, as shown in Figure 6.
  • Baffle 12 extends from one side of inner wall 10 to the other side of inner wall 10.
  • Baffle 12 may contain filter support ribs 15 located on its first surface 9, and filter support ribs 15a located on its second surface 9a as shown in Figure 6.
  • Housing inlet half 1a is identical to housing inlet half 1 with the exceptions that baffle 12 has been added to housing inlet half 1a, and the cross-sectional area of inlet 5a has been increased so that its cross-sectional area of inlet 5a will be greater than or equal to the cross- sectional area of the interior of tubing 81a shown in Figure 1 , and the width of inner wall 10a has been increased.
  • the volume of upstream chamber 13 of housing inlet half 1a will be less than the volume of upstream chamber 13 of housing inlet half 1, because of the volume taken up by baffle 12 and filter support ribs 15 and 15a.
  • Baffle 12 does not act as a partition wall to divide upstream chamber 13 into two distinct and separate chambers, because of the gaps 14 and 14a above and below the top and bottom respectively, of baffle 12.
  • the combined cross-sectional area of the two gaps should be large enough to prevent upstream chamber 13 from being divided into two separate and distinct chambers.
  • the cross-sectional area of each gap is defined as the cross- sectional area of the gap measured in a plane that passes through the center of the baffle and that is parallel to filter seal surface 7 and filter seal surface 7a.
  • the only purpose for adding baffle 12 to the housing inlet half is to reduce the volume of upstream chamber 13, and to add filter support ribs 15 and 15a which provide a means to keep the two BFFM's properly separated.
  • the filter support ribs could be replaced with an array of filter support pins, or by other means.
  • the baffle shown in Figure 6 has a first gap at the top and a second gap at the bottom, a single gap at the top or bottom or anywhere in between that prevents the baffle from acting as a partition wall to divide upstream chamber 13 into two distinct and separate chambers will suffice.
  • the gap may also be referred to as an aperture.
  • the fourth condition that can occur after tube clamp 95 is opens is: If the initial combined flow rate of the first and second BFFM's exceeds the flow rate of the biological fluid entering inlet 5, the BFFM 1 S will be wetted before the liquid level in upstream chamber reaches the top of upstream chamber 13, by a combination of liquid flow through the BFFM's below the liquid level in upstream chamber 13, and capillary wetting above the liquid level, thereby allowing the air to be purged from the BFFM's. Once the BFFM's have been wetted, the air in upstream chamber 13 above the liquid level will be trapped in upstream chamber 13, because the wetted BFFM's will not allow this air to be purged from upstream chamber 13.
  • the flow rate of biological fluid through the portion of the BFFM's below the top of the liquid level in chamber 13 will be much greater than the flow rate of biological fluid through the portion of the BFFM's above the top of the liquid level in chamber 13, so that the portions of the BFFM's above the liquid level will not be properly utilized.
  • BFFD 100 is used to remove leukocytes from blood or blood product
  • the leukocyte removing capability of the BFFM's may be reduced in the fourth condition when measured against the first condition above.
  • the filtered blood or blood product in the receiving blood bag's may contain more leukocytes than the filtered blood or blood product in the receiving blood bag's under the first condition.
  • the fourth condition can be rectified by reducing the initial flow rate through the BFFM's, by reducing the surface area of the BFFM's, or by increasing the resistance to flow through the BFFM's, or both. Alternately adding flow restrictions downstream of the BFFM's, such as the flow restrictions shown in Figure 2 in outlets 27, 27a will rectify the fourth condition. By adding the flow restrictions, it is not necessary to reduce the surface area of the BFFM's, thereby allowing greater total throughput of filtered blood or blood product without compromising the leukocyte reduction of the filtered product.
  • DDD 50 is used as an automatic draining means in biological fluid filtration system 1000, any other automatic draining means could be used, including any of the automatic draining means disclosed in patent application no. 10/934,881 or in application no. PCT/US2004/029026. Alternately the automatic draining means could be eliminated, in which case upstream chamber 13 would not drain after feed blood bag 98 is emptied.
  • a single sided BFFD with a single inlet and a single outlet, with a fluid flow path defined between the inlet and the outlet, with a BFFM interposed between the inlet and the outlet, and across the fluid flow path can benefit by adding a flow restriction downstream of the BFFM. If for example the single sided BFFD is used to remove leukocytes from a biological fluid, the initial flow rate of the biological fluid through the BFFM will start out high and decrease as the BFFM fouls. If the initial flow rate is too high the leukocyte removing capability of the BFFM may be reduced, so that fewer leukocytes per unit volume of filtered biological fluid will be removed from the biological fluid initially, than will be after the flow rate has been reduced due to fouling.
  • a single sided BFFD will have a single inlet and a single outlet, with a fluid flow path defined between the inlet and the outlet, with a BFFM interposed between the inlet and the outlet, and across the fluid flow path, with a flow restriction located downstream of the BFFM, with the fluid flow path flowing through the flow restriction.
  • a single sided BFFD such as BFFD 300 shown in Figure 8 that includes a single inlet 105 and a single outlet 127, with a fluid flow path defined between the inlet and the outlet, with BFFM 118 interposed between the inlet and the outlet, and across the fluid flow path that includes an upstream chamber 113 can benefit by adding a flow restriction downstream of the BFFM.
  • BFFD 300 can replace BFFD 100 in biological fluid filtration system 1000 shown in Figure 1 , with a single receiving blood bag connected to outlet 127.
  • upstream chamber 113 of BFFD 200 will rapidly fill with biological fluid from the bottom up.
  • upstream chamber 113 fills from the bottom up the initial air in upstream chamber 113 will be displaced by the biological fluid filling upstream chamber 113.
  • the displaced air will be forced through BFFM 118, into outlet 127. If however, once BFFM 118 has been wetted with biological fluid the flow rate through the BFFM may increase so that the flow rate through the BFFM will exceed the flow rate of biological fluid entering chamber 113 through inlet 105.
  • biological fluid will initially fill chamber 113 from the bottom to the top, and then after the BFFM has been wetted, the liquid level in chamber 113 will drop to a level below the top of chamber 113.
  • the flow rate of biological fluid through the portion of the BFFM below the top of the liquid level in chamber 113 will be much greater than the flow rate of biological fluid through the portion of the BFFM above the top of the liquid level in chamber 113, so that the portions of the BFFM above the liquid level will not be properly utilized.
  • BFFD 300 is used to remove leukocytes from blood or blood product, the leukocyte removing capability of the BFFM may be reduced compared to what it would be if the upstream chamber remained full throughout the filtration cycle. Hence the filtered blood or blood product in the receiving blood bag's may contain more leukocytes than the filtered blood or blood product should.
  • the problem can be rectified by adding a flow restriction to outlet 127 as shown in Figure 8.
  • the flow restriction is shown in Figure 8 as a long small diameter outlet.
  • the flow restriction should be sized so that the flow rate of biological fluid through the BFFM, and therefore through outlet 127 is less than or equal to the flow rate of biological fluid entering chamber 113 through inlet 105.
  • the flow restriction could be located anywhere downstream of the BFFM.
  • the flow restriction could be located in tubing 82 between outlet 127 and the receiving blood bag.
  • all or part of tubing 82 could have a smaller inside diameter than tubing 81 and tubing 81a to create the restriction downstream of the BFFM.
  • a second condition that can occur with single sided BFFD after tube clamp 95 is opens is: If the initial flow rate of BFFM 118 exceeds the flow rate of the biological fluid entering inlet 105, the BFFM will be wetted before the liquid level in upstream chamber reaches the top of upstream chamber 113, by a combination of liquid flow through the BFFM below the liquid level in upstream chamber 113, and capillary wetting above the liquid level, thereby allowing the air to be purged from the BFFM. Once the BFFM has been wetted, the air in upstream chamber 113 above the liquid level will be trapped in upstream chamber 113, because the wetted BFFM will not allow this air to be purged from upstream chamber 113.
  • the flow rate of biological fluid through the portion of the BFFM below the top of the liquid level in chamber 113 will be much greater than the flow rate of biological fluid through the portion of the BFFM above the top of the liquid level in chamber 113, so that the portions of the BFFM above the liquid level will not be properly utilized.
  • BFFD 300 is used to remove leukocytes from blood or blood product, the leukocyte removing capability of the BFFM may be reduced in this condition. Hence in this condition the filtered blood or blood product in the receiving blood bag may contain more leukocytes than desired.
  • This condition can be rectified by reducing the initial flow rate through the BFFM, by reducing the surface area of the BFFM, or by increasing the resistance to flow through the BFFM, or both. Alternately adding a flow restriction downstream of the BFFM, such as the flow restriction shown in Figure 8 in outlet 27 will rectify the fourth condition. If the flow restriction is added, is not necessary to reduce the surface area of the BFFM, thereby allowing greater total throughput of filtered blood or blood product without compromising the leukocyte reduction of the filtered product.
  • a double sided BFFD that lacks a partition wall, that includes a single inlet and a single outlet, with a first fluid flow path defined between the inlet and the outlet, with a first BFFM interposed between the inlet and the outlet, and across the first fluid flow path, with a second fluid flow path defined between the inlet and the outlet, with a second BFFM interposed between the inlet and the outlet, and across the second fluid flow path, can benefit by adding a flow restriction downstream of the first and second BFFM's. If for example such a double sided BFFD is used to remove leukocytes from a biological fluid, the initial flow rate of the biological fluid through the BFFM's will start out high and decrease as the BFFM's foul.
  • the leukocyte removing capability of the BFFM's may be reduced, so that fewer leukocytes per unit volume of filtered biological fluid will be removed from the biological fluid initially, than will be after the flow rate through the BFFM's has been reduced due to fouling.
  • restricting the flow of biological fluid through the BFFD by using a restriction downstream of both the BFFM's will produce a more uniform flow rate through the BFFM's throughout the entire filtration cycle, thereby increasing the leukocyte removal rate.
  • a double sided BFFD that lacks a partition wall will have a single inlet and a single outlet, with a first fluid flow path defined between the inlet and the outlet, with a first BFFM interposed between the inlet and the outlet, and across the first fluid flow path, with a second fluid flow path defined between the inlet and the outlet, with a second BFFM interposed between the inlet and the outlet, and across the second fluid flow path, with a flow restriction located downstream of both the first and second BFFM's, with the first and second fluid flow paths flowing through the flow restriction.
  • a double sided BFFD such as the ones disclosed in US patent no. 6,660,171 , and in US patent application no. 10/934,881 , that include a partition wall, and that include a single inlet and a single outlet, with a first fluid flow path defined between the inlet and the outlet, with a first BFFM interposed between the inlet and the outlet, and across the first fluid flow path, with a second fluid flow path defined between the inlet and the outlet, with a second BFFM interposed between the inlet and the outlet, and across the second fluid flow path, can benefit by adding a flow restriction downstream of the first and second BFFM's.
  • the initial flow rate of the biological fluid through the BFFM's will start out high and decrease as the BFFM's foul. If the initial flow rate is too high the leukocyte removing capability of the BFFM's may be reduced, so that fewer leukocytes per unit volume of filtered biological fluid will be removed from the biological fluid initially, than will be after the flow rate through the BFFM's has been reduced due to fouling. In this case restricting the flow of biological fluid through the BFFD by using a restriction downstream of both the BFFM's will produce a more uniform flow rate through the BFFM's throughout the entire filtration cycle, thereby increasing the leukocyte removal rate.
  • a double sided BFFD that includes a partition wall will have a single inlet and a single outlet, with a first fluid flow path defined between the inlet and the outlet, with a first BFFM interposed between the inlet and the outlet, and across the first fluid flow path, with a second fluid flow path defined between the inlet and the outlet, with a second BFFM interposed between the inlet and the outlet, and across the second fluid flow path, with a flow restriction located downstream of both the first and second BFFM's, with the first and second fluid flow paths flowing through the flow restriction.
  • a double sided BFFD such as the ones disclosed in US patent application no.
  • 10/693,757 that include a partition wall, and that include a single inlet and two outlets, with a first fluid flow path defined between the inlet and the first outlet, with a first BFFM interposed between the inlet and the first outlet, and across the first fluid flow path, with a second fluid flow path defined between the inlet and the second outlet, with a second BFFM interposed between the inlet and the second outlet, and across the second fluid flow path, can benefit by adding a flow restriction downstream of the first and second BFFM's. If for example such a double sided BFFD is used to remove leukocytes from a biological fluid, the initial flow rate of the biological fluid through the BFFM's will start out high and decrease as the BFFM's foul.
  • the leukocyte removing capability of the BFFM's may be reduced, so that fewer leukocytes per unit volume of filtered biological fluid will be removed from the biological fluid initially, than will be after the flow rate through the BFFM's has been reduced due to fouling.
  • restricting the flow of biological fluid through the BFFD by using a restriction downstream of both the BFFM's will produce a more uniform flow rate through the BFFM's throughout the entire filtration cycle, thereby increasing the leukocyte removal rate.
  • a double sided BFFD that includes a partition wall will have a single inlet and a first and second outlet, with a first fluid flow path defined between the inlet and the first outlet, with a first BFFM interposed between the inlet and the first outlet, and across the first fluid flow path, with a second fluid flow path defined between the inlet and the second outlet, with a second BFFM interposed between the inlet and the second outlet, and across the second fluid flow path, with a flow restriction located downstream of both the first and second BFFM's, with the first fluid flow path flowing through the first flow restriction, and with the second fluid flow path flowing through the second flow restriction.
  • a double sided BFFD 1 such as the ones disclosed in US patent application no. 10/693,757 that include a partition wall, and that include two inlets and a single outlet, with a first fluid flow path defined between the first inlet and the outlet, with a first BFFM interposed between the first inlet and the outlet, and across the first fluid flow path, with a second fluid flow path defined between the second inlet and the outlet, with a second BFFM interposed between the second inlet and the outlet, and across the second fluid flow path, can benefit by adding a flow restriction downstream of the first and second BFFM's.
  • the initial flow rate of the biological fluid through the BFFM's will start out high and decrease as the BFFM's foul. If the initial flow rate is too high the leukocyte removing capability of the BFFM's may be reduced, so that fewer leukocytes per unit volume of filtered biological fluid will be removed from the biological fluid initially, than will be after the flow rate through the BFFM's has been reduced due to fouling. In this case restricting the flow of biological fluid through the BFFD by using a restriction downstream of both the BFFM's will produce a more uniform flow rate through the BFFM's throughout the entire filtration cycle, thereby increasing the leukocyte removal rate.
  • a double sided BFFD that includes a partition wall will have two inlets and a single outlet, with a first fluid flow path defined between the first inlet and the outlet, with a first BFFM interposed between the first inlet and the outlet, and across the first fluid flow path, with a second fluid flow path defined between the second inlet and the outlet, with a second BFFM interposed between the second inlet and the outlet, and across the second fluid flow path, with a flow restriction located downstream of both the first and second BFFM's, with the first and second fluid flow paths flowing through the flow restriction.
  • the BFFD could include a first flow restriction located between the downstream side of the first BFFM and the outlet, and a second flow restriction located between the downstream side of the second BFFM and the outlet.
  • a double sided BFFD such as the ones disclosed in patent application no. 10/934,881 or in ' application no. PCT/US2004/029026, that include a solid partition wall, and that include two inlets and two outlets, with a first fluid flow path defined between the first inlet and the first outlet, with a first BFFM interposed between the first inlet and the first outlet, and across the first fluid flow path, with a second fluid flow path defined between the second inlet and the second outlet, with a second BFFM interposed between the second inlet and the second outlet, and across the second fluid flow path, can benefit by adding a first flow restriction downstream of the first BFFM, and a second flow restriction downstream of the second BFFM.
  • the initial flow rate of the biological fluid or fluids through the first and second BFFM's will start out high and decrease as the BFFM's foul. If the initial flow rate is too high through either of the BFFM's, the leukocyte removing capability of the BFFM's may be reduced, so that fewer leukocytes per unit volume of filtered biological fluid or fluids through either fluid flow path will be removed from the biological fluid or fluids initially, than will be after the flow rate through the BFFM's has been reduced due to fouling.
  • a double sided BFFD that includes a solid partition wall will have first inlet and a first outlet, with a first fluid flow path defined between the first inlet and the first outlet, with a first BFFM interposed between the first inlet and the first outlet, and across the first fluid flow path, with a second fluid flow path defined between the second inlet and the second outlet, with a second BFFM interposed between the second inlet and the second outlet, and across the second fluid flow path, with a first flow restriction located downstream of the first BFFM, with a second flow restriction located downstream of the second BFFM with the first fluid flow path flowing through the first flow restriction, and with the second fluid flow path flowing through the second flow restriction.
  • a double sided BFFD with or without a partition wall that includes a single inlet and a single outlet, with a first fluid flow path defined between the inlet and the outlet, with a first BFFM interposed between the inlet and the outlet, and across the first fluid flow path, with a second fluid flow path defined between the inlet and the outlet, with a second BFFM interposed between the inlet and the outlet, and across the second fluid flow path, can benefit by adding two flow restrictions downstream of the outlet as shown in Figure 7.
  • double sided BFFD 200 may or may not contain a partition wall.
  • the outlet of BFFD 200 is in fluid flow communication with the inlet of tee 70 via tubing 82b.
  • Side arm 70a of tee 70 is in fluid flow communication with the inlet of receiving blood bag 99 via tubing 82c
  • side arm 70b of tee 70 is in fluid flow communication with the inlet of receiving blood bag 99a via tubing 82d.
  • a first restriction may be included in side arm 70a or in tubing 82c
  • a second restriction may be included in side arm 70b or in tubing 82d. If the first and second restrictions provide equal back pressure to biological fluid flow from tubing 82b, then equal amounts of filtered biological fluid will flow into the two receiving blood bags. Furthermore as in the above cases, the two restrictions will restrict the flow of biological fluid through the BFFD, thereby producing a more uniform flow rate through the BFFM's throughout the entire filtration cycle, thereby increasing the leukocyte removal rate.
  • any other type of filter underdrain structure that provides the proper support for the BFFM can be used.

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • External Artificial Organs (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Dispositif, système et procédé de filtration de fluide biologique pour filtrer un fluide biologique. Le dispositif comprend un logement ayant une entrée, une première sortie et une seconde sortie, un premier canal d'écoulement du fluide étant défini entre l'entrée et la première sortie, un second canal d'écoulement de fluide étant défini entre l'entrée et la seconde sortie, un premier moyen de filtration de fluide biologique étant intercalé entre l'entrée et la première sortie et à travers le premier canal d'écoulement de fluide, et un second moyen de filtration du fluide biologique entre l'entrée et la seconde sortie et à travers le second canal d'écoulement de fluide. Le logement manque essentiellement d'une paroi de séparation solide entre le premier moyen de filtration de fluide biologique et le second moyen de filtration de fluide biologique. Une première restriction de flux peut être ajoutée en aval du premier moyen de filtration de fluide biologique, et une seconde restriction de flux peut être ajoutée en aval du second moyen de filtration de fluide biologique. Dans un autre mode de réalisation, le dispositif comprend un logement ayant une entrée et une sortie, un canal d'écoulement étant défini entre l'entrée et la sortie, un moyen de filtration de fluide biologique étant intercalé entre l'entrée et la sortie et à travers le canal d'écoulement de fluide, le dispositif comprenant en outre une restriction de flux en aval du moyen de filtration de fluide biologique.
EP07751426.3A 2007-02-22 2007-02-22 Appareil de filtration d'un fluide biologique à grande capacité Withdrawn EP2125135A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/004661 WO2008103142A1 (fr) 2007-02-22 2007-02-22 Appareil de filtration d'un fluide biologique à grande capacité

Publications (2)

Publication Number Publication Date
EP2125135A1 true EP2125135A1 (fr) 2009-12-02
EP2125135A4 EP2125135A4 (fr) 2014-04-16

Family

ID=39710326

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07751426.3A Withdrawn EP2125135A4 (fr) 2007-02-22 2007-02-22 Appareil de filtration d'un fluide biologique à grande capacité

Country Status (9)

Country Link
EP (1) EP2125135A4 (fr)
JP (1) JP5329437B2 (fr)
CN (1) CN101687117B (fr)
AU (1) AU2007347456B2 (fr)
BR (1) BRPI0721268A2 (fr)
CA (1) CA2679044A1 (fr)
EA (1) EA016521B1 (fr)
MX (1) MX2009009035A (fr)
WO (1) WO2008103142A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2554189B1 (fr) 2010-03-30 2017-10-11 Asahi Kasei Medical Co., Ltd. Filtre pour le traitement du sang
CN104487105B (zh) * 2012-07-25 2016-12-07 旭化成医疗株式会社 血液处理过滤器、血液回路以及血液处理方法
US10064988B2 (en) * 2013-06-20 2018-09-04 Fenwal, Inc. Biological fluid filters with port for optimized flow distribution
US9968738B2 (en) 2014-03-24 2018-05-15 Fenwal, Inc. Biological fluid filters with molded frame and methods for making such filters
US9796166B2 (en) 2014-03-24 2017-10-24 Fenwal, Inc. Flexible biological fluid filters
US10376627B2 (en) 2014-03-24 2019-08-13 Fenwal, Inc. Flexible biological fluid filters
US10159778B2 (en) 2014-03-24 2018-12-25 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US9782707B2 (en) 2014-03-24 2017-10-10 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
JP6947728B2 (ja) * 2015-09-14 2021-10-13 メディシーブ リミテッド 磁気濾過装置および方法
FR3055556B1 (fr) 2016-09-08 2018-10-12 Maco Pharma Unite de filtration comprenant des portions en dome
FR3055557B1 (fr) 2016-09-08 2018-10-12 Maco Pharma Sa Unite de filtration comprenant un bord peripherique courbe
CN111977724A (zh) * 2020-09-04 2020-11-24 史环环 一种水污染防治设备隔离装置

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2821762A1 (fr) * 2001-03-09 2002-09-13 Maco Pharma Sa Unite de filtration comprenant deux milieux filtrants distincts et systeme a poches le comprenant
US20050051486A1 (en) * 2003-09-05 2005-03-10 Peter Zuk Biological fluid filtration apparatus
US8337700B1 (en) * 2005-02-24 2012-12-25 Hemerus Medical, Llc High capacity biological fluid filtration apparatus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE265882T1 (de) * 1996-07-09 2004-05-15 Pall Corp Filtervorrichtung für biologische fluide mit einem leukocyten abreichernden medium
US6660171B2 (en) * 2000-03-27 2003-12-09 Peter Zuk, Jr. High capacity gravity feed filter for filtering blood and blood products
AU2001219539A1 (en) * 2000-09-05 2002-03-22 Wesley L. Bradford Reverse osmosis membrane and process for making same
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2821762A1 (fr) * 2001-03-09 2002-09-13 Maco Pharma Sa Unite de filtration comprenant deux milieux filtrants distincts et systeme a poches le comprenant
US20050051486A1 (en) * 2003-09-05 2005-03-10 Peter Zuk Biological fluid filtration apparatus
US8337700B1 (en) * 2005-02-24 2012-12-25 Hemerus Medical, Llc High capacity biological fluid filtration apparatus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2008103142A1 *

Also Published As

Publication number Publication date
EP2125135A4 (fr) 2014-04-16
WO2008103142A1 (fr) 2008-08-28
BRPI0721268A2 (pt) 2013-01-15
CN101687117B (zh) 2013-06-26
CA2679044A1 (fr) 2008-08-28
MX2009009035A (es) 2009-12-14
AU2007347456B2 (en) 2011-10-06
CN101687117A (zh) 2010-03-31
EA200901130A1 (ru) 2010-04-30
JP2010518962A (ja) 2010-06-03
EA016521B1 (ru) 2012-05-30
AU2007347456A1 (en) 2008-08-28
JP5329437B2 (ja) 2013-10-30

Similar Documents

Publication Publication Date Title
AU2007347456B2 (en) A high capacity biological fluid filtration apparatus
US8337700B1 (en) High capacity biological fluid filtration apparatus
US8361320B2 (en) Biological fluid filtration apparatus
AU725080B2 (en) Multiple element filter
JP5008643B2 (ja) 血液処理回路
US6221264B1 (en) White blood cell-removing device, white blood cell-removing apparatus and white blood cell-removing method
EP2659917B1 (fr) Filtre de fractionnement du sang
US7140497B2 (en) Selective deleukocytation unit for a platelet product
JP5297463B2 (ja) 血液処理器具
WO2006126497A1 (fr) Dispositif filtrant pour traitement de fluide corporel
US8763816B2 (en) Filter for processing blood
JP4272477B2 (ja) 血液成分採取装置
JP2013048962A (ja) 大容量の体液濾過装置
JP2007319542A (ja) 血球製剤処理装置および血球製剤処理回路
JP2005237791A (ja) 血液の濾過方法および血液の濾過システム
WO2019116220A1 (fr) Unité de filtre améliorée pour sang total et dérivés sanguins
WO2018174197A1 (fr) Filtre de séparation de sang et méthode de séparation de composant sanguin
JP4302685B2 (ja) 血液処理方法
JP2009101187A (ja) 血液成分採取回路

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090922

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140313

RIC1 Information provided on ipc code assigned before grant

Ipc: C02F 1/44 20060101ALI20140307BHEP

Ipc: A61M 1/02 20060101ALI20140307BHEP

Ipc: B01D 11/00 20060101AFI20140307BHEP

Ipc: B01D 61/00 20060101ALI20140307BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140902